Vorasidenib
INDIGO
Servier · Phase 3 · Active, not recruiting · Enrollment 331
| Arm | Reported safety |
|---|---|
| Vorasidenib 40 mg daily | grade 3 or higher adverse events: 22.8%, NEJM 2023 (placebo 13.5%)grade 3 or 4 ALT increase (pooled): 9%, labelgrade 3 or 4 AST increase (pooled): 4.8%, labelpermanent discontinuation for ALT elevation: 2.9%, label |
A count stays a count. This page does not turn a count into a percent.